Aratana Therapeutics

Aratana Therapeutics, Inc. is a fast-growing pet therapeutics company headquartered in Kansas City with offices in Boston, Massachusetts, San Diego, California and Leuven, Belgium. We are focused on licensing, developing and commercializing innovative biopharmaceutical products for cats and dogs. Our company means "new beginning" and it defines our mission to develop safe and effective therapeutics for serious unmet and underserved medical needs in pets, and to deliver these cutting-edge options to veterinarians. We are uniquely positioned because we're operating at the intersection of human and animal science - taking advances in human medicine and applying to the unmet and underserved needs of pets.
Aratana means “new beginning” and it defines our mission of developing safe and effective therapeutics for unmet or underserved medical conditions in pets. Our goal is to provide veterinarians and pet owners with new therapeutics that are driven by science and specifically made for pets. We believe pets are family and they deserve the best quality care.
Aratana Therapeutics was founded in 2010, in the heart of the Kansas City Animal Health Corridor, with the vision of finding the best human drug development opportunities and applying them to veterinary medicine. Our team of experts, who have decades of experience in human health, animal health, biotechnology and other functional areas, paired with a lifelong love for pets, are committed to helping raise the standard of care for pets in order to help extend and improve the lives of cats and dogs. We have the pleasure of coming to work every day and putting our passion into making a difference for pets.
Our dedication has led us to develop a pipeline of novel therapeutics focused in area of osteoarthritis, post-operative pain management, inappetence, allergy, lymphoma and osteosarcoma, viral diseases and other unmet pet health needs.

Company Growth (employees)
Type
Public
HQ
Leawood, US
Founded
2010
Size (employees)
56 (est)
Aratana Therapeutics was founded in 2010 and is headquartered in Leawood, US

Key People at Aratana Therapeutics

Louise MawHinney

Louise MawHinney

CFO
Ernst Heinen

Ernst Heinen

Head of Drug Evaluation and Development
John Ayers

John Ayers

General Counsel & Secretary
James Miller

James Miller

Controller
Marie-Paul Lachaud

Marie-Paul Lachaud

Head of Business & Product Development Europe

Aratana Therapeutics Office Locations

Aratana Therapeutics has offices in Leawood, Boston, San Diego and Leuven
Leawood, US (HQ)
340 11400 Tomahawk Creek Pkwy
Leuven, BE
1 Ambachtenlaan
San Diego, US
200a 10451 Roselle St
Boston, US
545 Boylston St

Aratana Therapeutics Data and Metrics

Aratana Therapeutics Financial Metrics

Aratana Therapeutics's revenue was reported to be $38.6 m in 2016
Numbers are in $, USD

Revenue (Y, 2016)

38.6 m

Revenue growth (Y, 2015 - Y, 2016), %

5586%

Gross profit (Y, 2016)

35.4 m

Gross profit margin (Y, 2016), %

92%

Net income (Y, 2016)

(33.6 m)

EBIT (Y, 2016)

(30.8 m)

Market capitalization (21-Jun-2017)

259.6 m

Closing share price (21-Jun-2017)

7

Cash (31-Dec-2016)

87.3 m
Aratana Therapeutics's current market capitalization is $259.6 m.
FY, 2013FY, 2014FY, 2015Y, 2016

Revenue

123 k767 k678 k38.6 m

Revenue growth, %

524%(12%)5586%

Cost of goods sold

108 k365 k3.1 m

Gross profit

15 k434 k313 k35.4 m

Gross profit Margin, %

12%57%46%92%

Operating expense total

42 m42 m89.8 m69.4 m

EBIT

(41.9 m)(41.6 m)(89.5 m)(30.8 m)

EBIT margin, %

(34102%)(5425%)(13200%)(80%)

Interest expense

432 k1.6 m3.4 m

Interest income

75 k189 k385 k

Pre tax profit

(19.7 m)(85.8 m)(33.6 m)

Income tax expense

15.5 m1.7 m1.7 m

Net Income

(26.2 m)(38.8 m)(84.1 m)(33.6 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

41.1 m9.8 m26.8 m87.3 m

Accounts Receivable

352 k60 k87 k

Inventories

274 k427 k1.3 m11.1 m

Current Assets

48.5 m99.9 m89 m101.5 m

PP&E

98 k620 k2.6 m1.9 m

Goodwill

20.8 m41.4 m39.8 m39.4 m

Total Assets

115.5 m207.9 m147.1 m151.4 m

Accounts Payable

2.3 m1.5 m1.4 m7.4 m

Current Liabilities

16.9 m9.5 m5.7 m34.7 m

Additional Paid-in Capital

112.5 m255 m263.9 m286.9 m

Retained Earnings

(68 m)(152 m)(185.6 m)

Total Equity

86 m181.8 m101.6 m90.4 m

Financial Leverage

1.3 x1.1 x1.4 x1.7 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(4.3 m)(38.8 m)(84.1 m)(33.6 m)

Depreciation and Amortization

395 k2 m1.8 m379 k

Accounts Receivable

(102 k)281 k(27 k)

Inventories

(372 k)(879 k)(15 m)

Accounts Payable

1.5 m(1.1 m)(117 k)6.2 m

Cash From Operating Activities

(16.2 m)(32.2 m)(38.5 m)(11.3 m)

Cash From Investing Activities

(29.2 m)(100.1 m)33.7 m57.3 m

Cash From Financing Activities

72.5 m101 m21.9 m14.6 m

Interest Paid

357 k942 k
Y, 2016

Financial Leverage

1.7 x

Aratana Therapeutics Market Value History

Aratana Therapeutics Online and Social Media Presence

Aratana Therapeutics Company Life and Culture

You may also be interested in